Takhzyro (lanadelumab-flyo)

Description

Takhzyro (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in adults and children aged 2 years and older. It works by blocking the activity of plasma kallikrein, a protein that plays a key role in causing swelling during HAE attacks. Takhzyro is given as a subcutaneous injection (under the skin), typically once every two or four weeks, and helps reduce the frequency and severity of swelling episodes in patients with HAE.